Vous avez cherché: baziliksimab (Slovène - Anglais)

baziliksimab
basiliximab

baziliksimab ne povzroči mielosupresije.
basiliximab does not cause myelosuppression.

na te dogodke baziliksimab ni vplival.
these events were not influenced by basiliximab.

zdravilo vsebuje zdravilno učinkovino baziliksimab.
it contains the active substance basiliximab.

vsi bolniki so prejemali baziliksimab, mofetilmikofenolat in kortikosteroide.
all patients received basiliximab, mmf, and corticosteroids.

zdravilna učinkovina v zdravilu simulect, baziliksimab, je monoklonsko protitelo.
the active substance in simulect, basiliximab, is a monoclonal antibody.

simulect 10 mg prašek in vehikel za raztopino za injiciranje ali infundiranje baziliksimab
simulect 10 mg powder and solvent for solution for injection or infusion basiliximab

simulect 10 mg prašek za raztopino za injiciranje/ infundiranje baziliksimab intravenska uporaba
simulect 10 mg powder for solution for injection/ infusion basiliximab intravenous use

izmed 202 bolnikov so bili 104 randomizirani tako, da so prejemali baziliksimab, 98 pa jih je prejemalo placebo.
of the 202 patients, 104 were randomised to basiliximab and 98 to placebo.

zdravila simulect ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za baziliksimab ali katero koli drugo sestavino zdravila.
simulect should not be used in people who may be hypersensitive to basiliximab or any of the other ingredients.

baziliksimab ima možne nevarne imunosupresivne učinke na potek nosečnosti in na dojenčka, ki je izpostavljen baziliksimabu v materinem mleku.
basiliximab has potentially hazardous immunosuppressive effects with respect to the course of gestation and the suckling neonate exposed to basiliximab in breast milk.

pri tem se v skupini, ki je dobila baziliksimab, v primerjavi s placebom, ni povečal obseg neželenih dogodkov ali okužb.
in the original phase iii studies during the first 3 months post-transplantation, 14% of patients in the basiliximab group and 27% of patients in the placebo group had an acute rejection episode treated with antibody therapy (okt 3 or antithymocyte globulin/ antilymphocyte globulin (atg/ alg)), with no increase in adverse events or infections in the basiliximab group as compared to placebo.

po 6 mesecih je do izgube presadka prišlo pri 6% bolnikov, ki so prejemali baziliksimab, in pri 10% bolnikov, ki so prejemali placebo.
graft loss occurred in 6% of basiliximab-treated and 10% of placebo-treated patients by 6 months.

incidenca smrtnih izidov in vzrokov smrti po dvotirnem ali tritirnem zdravljenju je bila v skupini z baziliksimabom (2,9 %) in placebom (2,6 %) podobna; najpogostejši vzrok smrti v obeh tretiranih skupinah so bile okužbe (baziliksimab = 1,3 %, placebo = 1,4 %).
the incidence and causes of deaths following dual or triple therapy were similar in basiliximab (2.9%) and placebo groups (2.6%), with the most common cause of deaths in both treatment groups being infections (basiliximab = 1.3%, placebo = 1.4%).